A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis
Phase of Trial: Phase III
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Ataluren (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors PTC Therapeutics
- 05 Oct 2017 This trial was completed in Greece (end date: 2017-06-02), according to European Clinical Trials Database.
- 26 Sep 2017 This trial has been completed in Spain as per European Clinical Trials Database record.
- 30 May 2017 Planned End Date changed from 1 Oct 2017 to 1 May 2017.